DATASET 2026-08-0941 PROGRAMS INDEXEDTIRZEPATIDE ALL-IN $215–$597/MOEVERY FIGURE CAPTURE-DATED & SOURCE-LINKED
TopGLP1Providers.comverified price index
VERIFIED 2026-08-09

Found vs Henry Meds vs OrderlyMeds (2026)

On tirzepatide, the order is Found ($289) → OrderlyMeds ($299) → Henry Meds ($349) — gaps of $10 and then $50 a month, a $720 spread across a year between first and last. All-in figures, 10 mg basis, captured 2026-08-09.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

The three records, one screen

Found: the record, condensed

On tirzepatide, the number that matters at Found is $289 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. It is a flat structure: 2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

There is no membership line. $289 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

To place the number: #6 of 17 verified programs, with the floor $74/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $160 a month. A year at this figure: $3,468 monthly-billed.

Found’s semaglutide program bills $289 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. Because pricing is flat across the ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), a dose increase at Found is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

There is no membership line. $289 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

Context for that figure: it ranks #15 of 20 in the verified semaglutide index — $156/month above the floor (Oak Longevity, $133) — and sits $60 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $3,468.

Operationally at Found: shipping included; commitment none month-to-month; prepaid terms for lowest rate; cancellation membership recurs; prepaid terms are paid up front; pharmacy not publicly named — ask in writing before paying; states: most states; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Found page · visit Found ↗

OrderlyMeds: the record, condensed

Start with the load-bearing figure: $299 a month, all-in, is what OrderlyMeds charges for tirzepatide at the 10 mg basis. It is a flat structure: 2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

To place the number: #8 of 17 verified programs, with the floor $84/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $150 a month. A year at this figure: $3,588 monthly-billed.

On semaglutide, the number that matters at OrderlyMeds is $149 a month all-in — the figure at the 2.4 mg maintenance basis this whole site ranks on. Because pricing is flat across the ladder (0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg), a dose increase at OrderlyMeds is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $149 is the whole subscription, which makes OrderlyMeds unusually easy to compare and unusually easy to leave.

Context for that figure: it ranks #4 of 20 in the verified semaglutide index — $16/month above the floor (Oak Longevity, $133) — and sits $200 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $1,788.

Operationally at OrderlyMeds: shipping included; commitment none stated; cancellation not published; pharmacy not publicly named — ask in writing before paying; states: not published; evidence no public price, captured 2026-08-05. The full record with source and archive links: the OrderlyMeds page · visit OrderlyMeds ↗

Henry Meds: the record, condensed

Henry Meds’s tirzepatide program bills $349 a month once every mandatory fee is counted, measured at the 10 mg maintenance basis. Because pricing is flat across the ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)), a dose increase at Henry Meds is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $349 is the whole subscription, which makes Henry Meds unusually easy to compare and unusually easy to leave.

To place the number: #10 of 17 verified programs, with the floor $134/month below at NexLife ($215); the approved-product yardstick (Zepbound (LillyDirect)) sits at $449, so the compounded case here is worth $100 a month. A year at this figure: $4,188 monthly-billed.

Henry Meds’s semaglutide program bills $179 a month once every mandatory fee is counted, measured at the 2.4 mg maintenance basis. It is a flat structure: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

There is no membership line. $179 is the billed total — consultation and clinical review are inside it, and no platform fee recurs beside it, which removes the most common way advertised GLP-1 prices understate billed ones.

Context for that figure: it ranks #9 of 20 in the verified semaglutide index — $46/month above the floor (Oak Longevity, $133) — and sits $170 under the brand benchmark (Wegovy (NovoCare), $349 at maintenance). Annualized, a monthly-billed year here runs $2,148.

Operationally at Henry Meds: shipping included; commitment none month-to-month; cancellation check terms before prepaying; pharmacy not publicly named — ask in writing before paying; states: most states; evidence third-party reported, captured 2026-08-05. The full record with source and archive links: the Henry Meds page · visit Henry Meds ↗

Prices, gaps, and what sits inside them

Found holds the low ground at $289 — dose-flat, so that figure is a ceiling with no membership attached. OrderlyMeds follows at $299 (+$10/mo, $120/yr). Henry Meds tops the trio at $349 (+$60/mo over the leader, $720/yr) — note its record’s watch-out below.

The semaglutide picture reshuffles the order: OrderlyMeds $149 → Henry Meds $179 → Found $289 — a reminder that molecule choice and provider choice are separate decisions, priced separately in the semaglutide index.

Who wins what

Cheapest month-to-month: Found ($289); cheapest 12-month path: Found ($3,468); cheapest semaglutide of the three: OrderlyMeds ($149).

Every winner above is a computation, not a placement; the pairwise pages carry the full duels: Found vs OrderlyMeds · Found vs Henry Meds · OrderlyMeds vs Henry Meds.

Everything besides the three prices

Memberships: Found none; OrderlyMeds none; Henry Meds none. Structures: Found dose-flat; OrderlyMeds dose-flat; Henry Meds dose-flat. Pharmacies: Found not named; OrderlyMeds not named; Henry Meds not named. States: Found — most states; OrderlyMeds — not published; Henry Meds — most states. Exit terms: Found — membership recurs; prepaid terms are paid up front; OrderlyMeds — not published; Henry Meds — check terms before prepaying.

The census reading: where all three match on an axis, that axis cannot break the tie and the price column rules; where they split — a membership here, an unnamed pharmacy there — the split is usually worth more than a small price gap, because structure is what you live with after month one. Evidence for all three: Found third-party reported (2026-08-05); OrderlyMeds no public price (2026-08-05); Henry Meds third-party reported (2026-08-05).

The trio on semaglutide, across time

3 mo: OrderlyMeds $447 vs Henry Meds $537 vs Found $867 6 mo: OrderlyMeds $894 vs Henry Meds $1,074 vs Found $1,734 12 mo: OrderlyMeds $1,788 vs Henry Meds $2,148 vs Found $3,468 — monthly-billed totals; prepaid paths where published appear on each provider page.

The trio, annualized

Found: $3,468/yr monthly-billed; OrderlyMeds: $3,588/yr monthly-billed; Henry Meds: $4,188/yr monthly-billed. Across two years at monthly billing the first-to-last spread widens to $1,440 — the horizon at which structure (prepaid ladders, flat pricing, membership drag) matters more than the sticker.

The elimination read

A three-way choice is really two eliminations, so run them in order. Eliminate Henry Meds first unless it names its edge: at $349 it carries a $60/month premium over the floor of this trio — $720 a year, about 2.5 extra months of therapy at Found’s rate — and a premium that size must point at a specific line in its record (its particular program design) or it is decoration. Then interrogate OrderlyMeds’s middle ground: nothing structural — its case is purely situational; if that specific thing is on your personal ledger, the $10/month over the floor can be rational — if not, the middle is where budgets go to leak. What survives is Found at $289, which wins by default rather than by argument — exactly how a price index should crown things — subject to the two checks no ranking can run for you: your state at intake, and your prescriber on the medication itself.

The same trio on best published rate: Found $289 → OrderlyMeds $299 → Henry Meds $349 — all three price month-to-month only at capture. Short-horizon totals, monthly-billed: 3 months — Found $867, OrderlyMeds $897, Henry Meds $1,047; 6 months — Found $1,734, OrderlyMeds $1,794, Henry Meds $2,094. 0 of the three publish a prepaid path below their own monthly billing; the twelve- and twenty-four-month table below carries those, labeled.

The record-quality read, scored on the five checkable disclosures this index tracks (maintenance price, named pharmacy, published states, published cancellation terms, source-verified capture): Found 3/5, OrderlyMeds 3/5, Henry Meds 3/5. A three-way tie — disclosure cannot break this trio, so the price and structure columns above carry the whole decision. The three match on every disclosure axis, which is rare and worth noting in their favor collectively. Scores recompute from the public records like everything else here.

Read as a decision: start from Found and make the other two argue upward. OrderlyMeds’s case is its structure; Henry Meds’s case must be worth $720 a year in named features — the honest unit being months of medication (2.5 of them at the floor rate). The pairwise pages above hold each argument in full, and the calculator holds your version of it.

Frequently asked

Which is cheapest: Found, Henry Meds, or OrderlyMeds?

Found, at $289/month all-in tirzepatide — $10 under OrderlyMeds and $60 under Henry Meds; on semaglutide the cheapest of the three is OrderlyMeds at $149. Captured 2026-08-09.

Which of the three is best over a full year?

Found’s best path prices twelve months at $3,468; monthly-billed years run Found $3,468, OrderlyMeds $3,588, Henry Meds $4,188.

Are these rankings paid or editorial?

Neither — they are sorts of the public dataset on the all-in maintenance basis, regenerated on every data change; the methodology page defines the basis and the JSON lets you recompute every figure here.